The Life Sciences team advised Palleon Pharmaceuticals on its collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN).
Palleon is a leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. Palleon’s EAGLE (Enzyme-Antibody GLycan Editing) platform enables new target discovery, patient selection, and the development of novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program, E-602, is a first-in-class human sialidase enzyme therapeutic developed from the company’s EAGLE platform.
Under the terms of the agreement, Henlius received an exclusive China license to Palleon’s E-602. Palleon is eligible to receive up to $95.3 million in certain predetermined development and commercial milestones, in addition to royalties upon E-602 commercialization in China. Henlius shall perform and fund E-602 development in China in combination with HANLIKANG for the treatment of LN. This partnership expands upon Palleon and Henlius’ ongoing collaboration in oncology formed in June 2022 to co-develop targeted sialidase therapies in cancer, in which collaboration Goodwin also represented Palleon.
For more details, read the press release and articles in Businesswire, and BioSpace.